[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PikaCapital "$arwr stop obsessing over whats going happen to $srpt. Arrowhead gets to keep original payment and will get rights back to all compounds if Sarepta can't keep paying. It's a win win regardless of what happens to Sarepta"
@PikaCapital on X 2025-07-19 17:53:33 UTC 2756 followers, 6848 engagements

"@avidresearch $gmab main composition patent expires around that timeframe I believe. But this is not a clean cut case here. J&J will use additional patents (e.g. Darzalex Faspro method of use) to extend life and prevent bio similars until mid 2030s"
@PikaCapital on X 2025-07-17 20:43:17 UTC 2755 followers, XXX engagements

"$SRPT survived longer than I expected actually. Stop blaming FDA. It's always been a controversial play / a ticking bomb. Now they need to shift the entire focus to $ARWR compounds. But not sure about the path forward here for them with that debt pile. $XBI"
@PikaCapital on X 2025-07-24 16:46:18 UTC 2760 followers, 4408 engagements

"$arwr nice and steady recovery from that disgusting April selloff. Even more bullish now after $srpt restructuring and shifted focus on licensed compounds from Arrowhead"
@PikaCapital on X 2025-07-17 20:33:33 UTC 2756 followers, 1537 engagements

"Palantir $PLTR is certainly a cult and ticking bomb🎈📌 but $NET is not worth 30x multiple lol. And I'm saying this as a huge fan of this company"
@PikaCapital on X 2025-07-25 21:18:20 UTC 2760 followers, XXX engagements

"So no one cared when $arwr and $srpt signed and a deal and now we got XX% haircut because of drama at Sarepta"
@PikaCapital on X 2025-07-21 14:53:17 UTC 2760 followers, 7047 engagements